Suppression of Wnt Signaling by Dkk1 Attenuates PTH-Mediated Stromal Cell Response and New Bone Formation  by Guo, Jun et al.
Cell Metabolism
ArticleSuppression of Wnt Signaling by Dkk1
Attenuates PTH-Mediated Stromal Cell
Response and New Bone Formation
Jun Guo,1 Minlin Liu,1 Dehong Yang,1,5 Mary L. Bouxsein,2 Hiroaki Saito,3 R.J. Sells Galvin,4 Stuart A. Kuhstoss,4
Clare C. Thomas,1 Ernestina Schipani,1 Roland Baron,3 F. Richard Bringhurst,1 and Henry M. Kronenberg1,*
1Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
2Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
3Department of Oral Medicine, Harvard School of Dental Medicine, Boston, MA 02115, USA
4Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
5Present address: Department of Spinal and Orthopedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
*Correspondence: kronenberg.henry@mgh.harvard.edu
DOI 10.1016/j.cmet.2009.12.007SUMMARY
Parathyroid hormone (PTH) suppresses Dickkopf
1 (Dkk1) expression in osteoblasts. To determine
whether this suppression is essential for PTH-medi-
ated Wnt signaling and bone formation, we examined
mice that overexpress Dkk1 in osteoblasts (Dkk1
mice). Dkk1 mice were osteopenic due to abnormal
osteoblast and osteoclast activity. When fed a low-
calcium diet, and in two other models of hyperpara-
thyroidism, these mice failed to develop the peritra-
becular stromal cell response (‘‘osteitis fibrosis’’)
and new bone formation seen in wild-type mice.
Despite these effects of Dkk1 overexpression, PTH
still activated Wnt signaling in Dkk1 mice and in oste-
oblastic cells cultured from these mice. In cultured
MC3T3E1 preosteoblastic cells, PTH dramatically
suppressed Dkk1 expression, induced PKA-medi-
ated phosphorylation of b-catenin, and significantly
enhanced Lef1 expression. Our findings indicate
that the full actions of PTH require intact Wnt
signaling but that PTH can activate the Wnt pathway
despite overexpression of Dkk1.
INTRODUCTION
Parathyroid hormone (PTH) increases bone formation and, when
administered intermittently, increases bone mass (Hodsman
et al., 2005). The cellular and structural mechanisms underlying
this anabolic action of PTH are under intense study (Jilka, 2007).
The canonical Wnt pathway has been implicated in bone
formation. Initial evidence for involvement of this pathway in
bone development came from studies of human and mouse
mutations in low-density lipoprotein receptor-related protein
5 (Lrp5), which, like Lrp6, is a coreceptor for Wnt ligands
expressed in osteoblasts. In humans, Lrp5 loss-of-function
mutations lead to osteoporosis-pseudoglioma syndrome, which
is characterized by low bone density (Gong et al., 2001), while
gain-of-function mutations are associated with high bone mass
(Boyden et al., 2002). Recent data (Yadav et al., 2008), however,Cell Mshow that most of the effects of these mutations can be ex-
plained by actions of Lrp5 to lower serotonin production in the
intestine, with subsequent actions of this serotonin on receptors
on osteoblasts. Nevertheless, the effects of canonical Wnt
signaling directly in bone are profound. Studies of gain and
loss of function of b-catenin, a key component of canonical
Wnt signaling, in cells of the osteoblast lineage in mice demon-
strate that Wnt/b-catenin signaling is required for osteoblast dif-
ferentiation, stimulates osteoblast proliferation, and decreases
osteoclast formation. Inactivation of b-catenin in mesenchymal
progenitors or early osteoblastic cells prevents osteoblast differ-
entiation, indicating that Wnt/b-catenin signaling controls osteo-
blast differentiation (Day et al., 2005; Hill et al., 2005; Rodda and
McMahon, 2006). Transgenic overexpression of the high bone
mass mutant (G171V) of Lrp5 using the 3.6 kb collagen 1a(I)
promoter increases bone mass and bone formation rate (Babij
et al., 2003), while transgenic expression of b-catenin using the
2.3 kb collagen 1a(I) promoter to express b-catenin only in
mature osteoblasts has no effect on bone formation rate but
decreases osteoclast activity by increasing expression of osteo-
protegerin (OPG) (Glass et al., 2005); similarly, deletion of adeno-
matous polyposis coli (Apc), a suppressor of canonical Wnt
signaling, in mature osteoblasts leads to an increase in OPG
and a decrease in expression of receptor activated by nuclear
factor-kB ligand (RANKL) (Holmen et al., 2005).
Dickkopf 1 (Dkk1) negatively regulates canonical Wnt sig-
naling by binding to and antagonizing the Wnt coreceptors
Lrp5/6 (He et al., 2004). Dkk1 plays an important role in verte-
brate development, by regulating, for example, processes such
as anteroposterior patterning, limb development, and head
induction (Glinka et al., 1998; Marvin et al., 2001; Mukhopadhyay
et al., 2001). Recently Dkk1 has been implicated in bone forma-
tion and bone disease. Deletion of a single allele of the Dkk1 gene
in mice causes an increase in bone formation and bone mass
(Morvan et al., 2006). In contrast, overexpression of Dkk1 in oste-
oblasts leads to osteopenia (Li et al., 2006).
Several studies have explored links between PTH and Wnt
signaling pathways. Kulkarni et al. (Kulkarni et al., 2005) showed
that PTH administration to UMR106 osteoblastic cells changes
the expression of several components of the canonical Wnt
pathway and increases stabilized b-catenin in those cells. Simi-
larly, Tobimatsu et al. (Tobimatsu et al., 2006) showed that PTHetabolism 11, 161–171, February 3, 2010 ª2010 Elsevier Inc. 161
Figure 1. PTH Suppresses Dkk1 mRNA
Expression, and Overexpression of Dkk1 in
Osteoblasts Attenuates Wnt Signaling in
Bone
(A) The cultured rudiments were treated with
vehicle or human PTH(1–34) (PTH, 100 nM) for
6 hr and then processed for in situ hybridization
with 35S-labeled Dkk1 antisense riboprobe. White
spots (arrows) seen with dark field microscopy
show intensity of Dkk1 mRNAs in osteoblastic
cells.
(B) E16.5 tibiae were treated with vehicle (blue
bars) or PTH (pink bars) for indicated hours, and
then total RNA was isolated for qRT-PCR analysis
with the primers specific for Dkk1. Data are
expressed as percent vehicle-treated control;
error bars represent standard error (*p < 0.05
versus vehicle).
(C) Targeting construct for generation of trans-
genic mouse lines by pronuclear injection.
(D) In situ hybridization analysis of E18.5 and
6-week tibiae dissected from WT or Dkk1 trans-
genic mice (Tg) with S35-labeled riboprobes
specific for Dkk1 transgene mRNA (Tg-specific)
or for both endogenous and transgenic Dkk1
mRNA (Dkk1 mRNA).
(E) High-magnification bright field of Dkk1 in situ
hybridization in tibial primary spongiosa from
6-week-old WT and Tg mice. Black spots indicate
Dkk1 mRNAs in osteoblastic cells (arrows).
(F) qRT-PCR analysis of mRNA expression in
12-week-old humeri with primers that detect
both endogenous and transgenic Dkk1 mRNA.
(G) qRT-PCR analysis of mRNA expression in
6-week-old tibiae of TOPGAL mice with (Tg) or
without (WT) transgenic Dkk1 with primers for
Axin2 mRNA (filled bar) and TOPGAL mRNA
(open bar). Data are expressed as percent mRNA
level of WT, and error bars represent standard
error (n = 6, *p < 0.05 versus WT) (see also Figures
S1 and S2).
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recently, PTH/PTHrP receptor signaling has been shown to
result in binding of the receptor to Lrp6, phosphorylation of
Lrp6, and stabilization of b-catenin in osteoblasts (Wan et al.,
2008). Despite all these observations, little is known about the
contribution of Wnt signaling to the actions of PTH in vivo. We
noticed that PTH rapidly decreases the expression of Dkk1 in
bone explants, and we therefore chose to explore the hypothesis
that this suppression of Dkk1 is important for actions of PTH
in vivo by overexpressing Dkk1 in osteoblasts in a way that could
not be suppressed by PTH. High-level Dkk1 expression also
allowed an evaluation of the need for canonical Wnt signaling
for actions of PTH. Here we present studies using a Dkk1-over-
expressing transgenic mouse to determine the interrelationships
of PTH and Wnt signaling in vivo and in vitro.
RESULTS
PTH Negatively Regulates Dkk1 mRNA Expression
in Osteoblastic Cells
In an initial experiment using microarray analysis, we observed
a dramatic downregulation of Dkk1 mRNA after PTH treatment162 Cell Metabolism 11, 161–171, February 3, 2010 ª2010 Elsevier Inof fetal tibiae ex vivo (data not shown). In situ hybridization
showed that Dkk1 was expressed early in embryonic perichon-
drial cells adjacent to hypertrophic chondrocytes and later in
the trabecular osteoblasts, but not in chondrocytes (see Fig-
ure S1 available online). Acute PTH treatment of cultured tibia
at E14.5 and femur at E17.5 led to a dramatic fall of Dkk1
mRNA in perichondrial cells and in trabecular osteoblasts
(Figure 1A, arrows). A similar inhibition of Dkk1 mRNA expression
in cultured tibiae at E16.5 was shown by a quantitative real-time
PCR (qRT-PCR) analysis (Figure 1B). These observations
suggest that PTH-induced downregulation of Dkk1 mRNA might
lead to increased canonical Wnt signaling and mediate some
actions of PTH signaling in bone.
Generation of a Mouse Line Expressing Dkk1
in Osteoblasts
To examine the role of Dkk1 in osteoblast differentiation and the
role of suppression of Dkk1 in PTH action on bone, we generated
a mouse model in which transgenic Dkk1 is expressed under the
control of a 2.3 kb fragment of the mouse a1(I) collagen promoter
(Figure 1C). This promoter fragment drives gene expression in
mature osteoblasts (Miao et al., 2005). Dkk1 mRNA expressionc.
Figure 2. Low Bone Mass in Dkk1 Mice
(A) von Kossa stain of plastic sections from
12-week-old proximal tibiae.
(B) mCT analysis of 12-week-old distal femurs and
vertebrae.
(C) Histomorphometric analysis of 12-week-old
tibiae. Abbreviations: BFR, bone formation rate;
BV/TV, bone volume/total volume; Conn.density,
connectivity density; MAR, mineral apposition
rate; N.Ob/BS, osteoblast number per bone sur-
face; N.Oc/BS, osteoclast number per bone sur-
face; Ob.S/BS, osteoblast surface per bone
surface; Oc.S/BS, osteoclast surface per bone
surface; SMI, structure model index; Tb.N, trabec-
ular number; Tb.Sp, trabecular spacing; Tb.Th,
trabecular thickness. Results are given as
mean ± SD. Statistical analysis was performed
by Student’s t test. For all panels, *p < 0.05 and
**p < 0.01 versus WT (n = 6–8) (see also Figure S3).
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8-week-old femurs with transgene-specific primers and primers
for both endogenous and transgenic Dkk1 (Fleming et al., 2008).
Dkk1 mRNA expression in three independent transgenic lines
was significantly higher than that in the wild-type (WT) littermates
(data not shown). For subsequent experiments, we utilized one
line with the highest level of Dkk1 transgene expression, though
all lines yielded similar results. As expected, the transgenic Dkk1
mRNA is highly expressed in osteoblastic cells, including peri-
chondral cells flanking hypertrophic chondrocytes and osteo-
blasts of both the cortical and trabecular region from the embry-
onic to the postnatal stages (Figures 1D and 1E). The probe
specific for the Dkk1 transgene mRNA (Figure 1D) detected the
transgenic mRNA only in the transgenic but not in the WT
bone. qRT-PCR analysis demonstrated that the level of Dkk1
mRNA in the transgenic humeri at 12 weeks of age was at least
40-fold higher than that observed in the WT rudiments
(Figure 1F).
To determine the effect of overexpression of Dkk1 on canon-
ical Wnt signaling in bone, Dkk1 transgenic mice were mated
to Wnt reporter (TOPGAL) mice that express the lacZ geneCell Metabolism 11, 161–171encoding E. coli b-galactosidase under
the control of three Lef1/Tcf consensus
binding sites linked to a minimal promoter
(DasGupta and Fuchs, 1999). Expression
of the transgene-specific, E. coli b-galac-
tosidase mRNA, as assessed by qRT-
PCR analysis, was greatly diminished
(by 74%) in bones from 6-week-old
Dkk1 mice compared to those in WT
littermates (Figure 1G). A comparable
decrease in expression of mRNA encod-
ing Axin2, which has been shown to be
a Wnt-responsive gene in many tissues,
was also observed in Dkk1 mice (Fig-
ure 1G). To determine whether decreased
canonical Wnt signaling in bone was
mainly due to continuing Dkk1 overex-
pression (as opposed to a decrease inosteoblast number caused by chronic Dkk1 secretion), we next
examined the effect of an anti-Dkk1 antibody on Wnt reporter
and Axin2 mRNA expression in vivo. Administration of anti-
Dkk1 antibody increased both TOPGAL and Axin2 mRNA
expression 2-fold, 24 hr after injection in Dkk1 transgenic;
TOPGAL mice, but not in TOPGAL mice without the Dkk1 trans-
gene (Figure S2), suggesting that anti-Dkk1 antibody efficiently
neutralizes Dkk1 protein and that the level of suppression of
Wnt signaling by Dkk1 in these mice at least partly reflects the
ongoing actions of Dkk1 protein. Thus, overexpression of Dkk1
in osteoblastic cells suppresses canonical Wnt signaling in bone.
Dkk1 Mice Exhibit Low Bone Mass
To assess bone mass in Dkk1 mice, both tibiae and femurs at
12 weeks of age were examined. Histology of transgenic tibiae
revealed a substantial reduction in mineralized trabeculae in
the metaphyseal trabecular regions (Figure 2A). This decrease
in bone mass was further demonstrated by microcomputed
tomographic (mCT) analysis (Figure 2B). The mCT analysis
showed a decrease in bone volume by more than 40% or 25%
in femurs and vertebrae of the Dkk1 mice, respectively. This, February 3, 2010 ª2010 Elsevier Inc. 163
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connectivity density, and structure model index, as well as with
an increase in trabecular separation (Figure 2B).
Decreased Osteoblast Activity in Dkk1 Mice
To assess whether the decreased bone mass observed in Dkk1
mice could be due to reduced osteoblast activity, dynamic histo-
morphometry was performed in 12-week-old tibiae (Figure 2C).
All measures of osteoblast number and activity were decreased
in Dkk1 mice. Osteoblast number and osteoblast surface were
decreased, with a corresponding decrease in mineral apposition
rate and bone formation rate, which was decreased more than
60% (Figure 2C). In situ hybridization consistently demonstrated
a decrease in expression of mRNAs encoding matrix proteins
secreted by osteoblasts in Dkk1 mice (Figure S3A). To assess
whether decreased osteoblast number and osteoblast activity
was partly due to alteration in proliferation rate, BrdU incorpora-
tion rate was measured in the primary trabecular compartment of
12-day-old tibia and femur. The percentage of BrdU-positive
osteoblastic cells was decreased by 42% in the transgenic
primary spongiosa (WT, 13.3% ± 1.6%, versus Dkk1 mice,
7.6% ± 1.8%; n = 6 animal pairs per group; p < 0.05 paired
t test), while the percentage of BrdU-positive cells in the chon-
drocytes of the proliferative region of the growth plate was
similar (WT, 10.6% ± 1.4%, versus Dkk1 mice, 9.4% ± 1.8%).
Further, the percentage of cells undergoing apoptosis in the
primary spongiosa, determined by TUNEL labeling, was signifi-
cantly increased in Dkk1 mice (WT, 4.2% ± 0.8%, versus Dkk1
mice, 5.9% ± 0.7%; p < 0.05 paired t test). Thus, the decreased
number of osteoblasts in this region is explained by decreased
proliferation and increased apoptosis.
Increased Osteoclast Activity in the Primary Spongiosa
of Dkk1 Mice
Targeted disruption of b-catenin in differentiated osteoblasts
leads to low bone mass due to increased osteoclast activity, in
association with a decrease in production of OPG (Glass et al.,
2005; Holmen et al., 2005). Consistent with this observation,
blocking Dkk1 activity with either an anti-Dkk1 antibody in the
context of experimental multiple myeloma or with the Dkk1 anti-
sense oligonucleotide in the setting of oophorectomy in mice
was shown not only to increase bone formation but also to
reduce osteoclast number in vivo (Wang et al., 2007; Yaccoby
et al., 2007). To assess whether the decrease in trabecular
bone seen in Dkk1 mice could be partly due to increased osteo-
clast activity, expression of tartrate-resistant acid phosphatase
(TRAP), a marker for osteoclasts, was examined. The number
of multinucleated osteoclasts staining positive for TRAP was
increased in the primary spongiosa of the tibiae of 6-week-old
Dkk1 mice. This is consistent with increased mRNA expression
of TRAP, analyzed by in situ hybridization, in the same bone
(Figure S3B). The qRT-PCR analysis of 12 week humeri further
showed an increase in levels of mRNA encoding TRAP and
MMP9, two genes expressed by osteoclasts, whereas mRNA
levels of osteoblastic regulators of osteoclastogenesis RANKL
and OPG were increased and decreased, respectively, consis-
tent with the finding of increased osteoclast number (Figure S3C).
Serum TRAP-5b, a marker of osteoclast number, also was signif-
icantly increased in Dkk1 mice at 12 weeks of age (Figure S3D).164 Cell Metabolism 11, 161–171, February 3, 2010 ª2010 Elsevier InIn contrast, when osteoclasts were counted in the secondary
spongiosa histomorphometrically, no change in normalized
osteoclast surface or osteoclast numbers was noted (Figure 2C).
We cannot easily explain these differing results in the differing
microenvironments of the bones. Perhaps the action of Dkk1
to decrease osteoblast number might decrease osteoblastic
support of osteoclastogenesis and balance the decreased
OPG produced by these osteoblasts in the secondary spon-
giosa. The decreased OPG production by osteoblasts may
lead to these varying results. In any case, the increased number
of osteoclasts in the primary spongiosa might contribute to the
decrease in trabecular bone in growing Dkk1 mice.
Dkk1 Attenuates PTH-Mediated Bone Formation
and Stromal Cell Responses
Continuous administration of PTH increases bone formation and
causes accumulation of peritrabecular stromal cells, some of
which are probably osteoblast precursors (Lotinun et al., 2005).
To determine whether canonical Wnt signaling is essential for
PTH-mediated bone formation and the peritrabecular stromal
cell response expected after PTH elevation postnatally, bone
was examined in mice fed a low-calcium diet for 3 weeks to
induce sustained secondary hyperparathyroidism (data not
shown). As expected, WT mice fed the low-calcium diet dis-
played large amounts of disorganized bone and extensive peri-
trabecular stromal cell accumulation. Such stromal cells strongly
express mRNAs encoding a1(I) collagen and osteopontin,
consistent with the idea that they are preosteoblasts (Figure 3,
Figures S4 and S5, and data not shown). Masson-Goldner
trichrome stain demonstrated that the disorganized bone con-
tained a high density of osteocytes and irregularly deposited
mineral (Figure 3 and Figure S4), suggesting that such disorga-
nized bone is woven bone and presumably represents poorly
organized, newly formed bone. In contrast, Dkk1 mice failed to
develop the peritrabecular stromal cell and woven bone
response seen in the WT mice (Figure 3 and Figures S4 and
S5) and uniquely exhibited tibial fractures in some mice (Fig-
ure S5B). Moreover, osteoclast activity in the primary spongiosa
was more strongly increased in Dkk1 mice fed a low-calcium diet
compared to that in the WT control mice (Figure S5C). These
observations suggest that a certain amount of Wnt signaling is
required to enable PTH to induce the peritrabecular stromal
cell response. Further, the suppression of Dkk1 expression by
PTH in WT mice may thus contribute to the peritrabecular
stromal cell response.
To further determine whether overexpression of Dkk1 attenu-
ated PTH-mediated peritrabecular stromal cell responses and
bone formation, we next examined the effect of a second model
of hyperparathyroidism, continuous PTH infusion, on bone
remodeling in Dkk1 mice. Continuous infusion of human PTH
for 2 weeks increased metaphyseal trabecular bone formation
and produced an accompanying peritrabecular stromal cell
response in WT mice, but not in Dkk1 mice, whereas such PTH
infusion caused loss of metaphyseal trabecular bone in Dkk1
mice (Figures 4A and 4B). Consistent with the observed
alterations in metaphyseal trabecular bone volume after PTH
infusion, levels of serum N-terminal propeptide of type I procol-
lagen (PINP), a marker of bone formation, were increased in
WT mice but decreased in Dkk1 mice, while levels of serumc.
Figure 3. AttenuatedStromalCellResponse
and New Bone Formation in Dkk1 Mice with
Secondary Hyperparathyroidism
(A) Both von Kossa and Masson-Goldner tri-
chrome stain were performed on plastic sections
of proximal tibiae of 6-week-old mice fed a low-
calcium diet or control diet for 3 weeks. von Kossa
stain reveals mineral in bone, and Masson-Gold-
ner trichrome stain demonstrates extensive peri-
trabecular fibroblast-like cell accumulation (arrow-
heads) and substantial woven bone-like newly
formed bone (with high density of osteocytes
and less mineral as stained in red, arrows), partic-
ularly in the metaphyseal trabecular regions as
indicated in a lower-magnification view, in WT
but not in Tg mice fed the low-calcium diet.
(B) The bar graph shows measurements of percent
of the bone volume formed by the ‘‘fibrotic’’ cells of
the peritrabecular stromal cell response. Data are
represented as percent fibroblastic volume (Fb.V)/
bone volume (BV), and error bars represent stan-
dard error, n = 6; *p < 0.05 versus control diet
(see also Figures S4 and S5).
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tion of osteoclastic digestion of collagen and, therefore, a bone
resorption marker, were elevated in both groups of mice
(Figure 4C).
The two hyperparathyroid models presented so far exhibit
abnormal calcium metabolism with low and high blood calcium
levels, respectively. To explore a third relevant model (Jansen
transgenic mouse) with normal levels of blood calcium, we
examined the effect of overexpression of Dkk1 on the extensive
stromal cell response caused by expression of a constitutively
active PTH receptor in osteoblasts in vivo. Mice overexpressing
Dkk1 were mated to Jansen transgenic mice that express
a constitutively active PTH receptor under the control of the
same a1(I) collagen promoter used in constructing the Dkk1
transgenic mice (Calvi et al., 2001). In contrast to the suppressive
effect of the Dkk1 transgene on bone formation, the Jansen
transgenic mice showed overproduction of trabecular bone
and an extensive peritrabecular stromal cell response, asCell Metabolism 11, 161–171reported previously (Calvi et al., 2001).
Interestingly, the extensive peritrabecular
stromal cell response characteristic of
the Jansen phenotype was strikingly
reduced in mice that expressed both
transgenes at the same time (Figure 5A).
Thus, three models of activation of the
PTHR in the setting of fixed, high Dkk1
expression all lead to suppression of the
peritrabecular stromal cell response.
Since these three models differ in their
affects on systemic mineral metabolism,
it is likely that the activation of the
receptor, rather than other subsequent
changes in mineral metabolism, explain
the response. These findings indicate
that activation of canonical Wnt signalingis essential for the PTH-mediated peritrabecular stromal cell
responses and new, woven bone formation.
Dkk1 Inhibits Proliferation and Colony Formation
of Primary BMSCs
To determine whether suppression of peritrabecular stromal cell
response observed in Dkk1 mice was partly due to inhibition of
commitment of osteoblastic progenitors, we examined the effect
of Dkk1 on proliferation and colony formation in WT-derived
primary bone marrow stromal cells (BMSCs). Treatment with
Dkk1 significantly inhibited proliferation and colony formation
of BMSCs, whereas Wnt3a stimulated both proliferation and
colony formation of BMSCs (Figure S6).
PTH Activates Canonical Wnt Signaling Even
in the Presence of Dkk1
We next investigated whether PTH activates Wnt signaling in
osteoblasts in vivo and whether PTH might fail to activate, February 3, 2010 ª2010 Elsevier Inc. 165
Figure 4. Strikingly Curtailed Bone Forma-
tion and Increased Bone Resorption in
Dkk1 Mice after Continuous PTH Infusion
(A and B) (A) Masson-Goldner trichrome stain
on plastic sections and (B) TRAP activity stain
on paraffin sections from proximal tibiae of
14-week-old WT and Tg mice receiving contin-
uous infusion of human PTH(1–34) (100 mg/kg/
day) (PTH) or of vehicle for 2 weeks. PTH infusion
increased metaphyseal trabecular bone formation
and stromal cell response (arrows in [A] in WT but
not in Tg mice).
(C) Serum PINP and CTX measured in 14-week-
old WT and Tg mice receiving continuous PTH
infusion for 2 weeks. Error bars represent standard
error, n = 6; *p < 0.05 versus day 0; and b, p < 0.05
versus WT.
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of Dkk1 to block the stromal cell response to PTH raises this
hypothesis. TOPGAL mice with or without the Dkk1 transgene
were acutely injected with human PTH. Consistent with the
idea that PTH activates the Wnt pathway in vivo in osteoblasts,
the level of expression of the E. coli b-galactosidase and of
Axin2 mRNA were increased roughly 2- to 3-fold in tibiae of
TOPGAL mice after PTH administration (Figure 5B). Further,
PTH had a similar (2- to 3-fold) effect on E. coli b-galactosidase
and on Axin 2 mRNA in bones from Dkk1 mice, albeit starting
from lower basal levels (see also Figure 1G); this finding suggests
that PTH activates canonical Wnt signaling even when Dkk1 is
not suppressed by PTH action.
We further examined the effect of PTH on Wnt signaling in
primary osteoblasts derived from both WT and Dkk1 mice.
Treatment with PTH significantly increased mRNAs encoding
TOPGAL, Axin2 and Tcf1, another known Wnt target gene166 Cell Metabolism 11, 161–171, February 3, 2010 ª2010 Elsevier Inc.(Rodda and McMahon, 2006), in both
types of primary osteoblasts. This effect
was attenuated by addition of Dkk1 in
WT osteoblasts and was enhanced by
addition of Dkk1 antibody in Dkk1
mouse-derived osteoblasts (Figures 6A
and 6B). In primary osteoblasts from
both WT and Dkk1 mice, PTH and
Wnt3a together induced higher levels of
mRNAs encoding Wnt target genes
compared with Wnt3a alone. We further
examined whether PTH stimulates the
nuclear translocation of b-catenin, which
is essential for activation of canonical
Wnt signaling, in the presence of Dkk1.
In WT-derived primary osteoblasts PTH
alone or with Wnt3a strongly increased
nuclear b-catenin, even in the presence
of Dkk1, while Wnt3a-induced nuclear
translocation of b-catenin was com-
pletely blocked by Dkk1 (Figure 6C).
Consistent with previous observation
(Bellido et al., 2005), we also observed
that PTH lowered levels of the mRNAencoding sclerostin (another Wnt antagonist) by about 60% in
both WT and Dkk1 mice and in primary osteoblasts from both
groups of mice (data not shown). Thus, some of the effects of
PTH, even in the presence of nonsuppressible Dkk1, might be
mediated by suppression of sclerostin production. To determine
other possible actions of PTH in the presence of excess Dkk1,
we studied Wnt signaling in MC3T3E1, the osteoblastic cell
line. Cells from this line are easy to transfect and differentiate
into mature osteoblasts but fail to synthesize sclerostin (data
not shown).
In MC3T3E1 cells transfected with a Wnt reporter gene, PTH
alone did not stimulate Wnt reporter activity, although Wnt3a
and LiCl induced the reporter activity by more than 300- or
30-fold over basal level, respectively (Figures S7A and S7B).
Interestingly, in the presence of a minimal amount of Wnt3a
(5 ng/ml), PTH generated a synergistic effect with Wnt3a on
Wnt reporter activity, and this synergistic effect was mimicked
Figure 5. Extensive Peritrabecular Stromal
Cell Responses Caused by Constitutively
Active PTH Receptor Were Strikingly Cur-
tailed in Dkk1 Mice, and PTH Activates
Wnt Signaling Even in the Presence of Dkk1
(A) Masson-Goldner trichrome stain of plastic
sections from 8-week proximal tibiae revealed
extensive peritrabecular fibroblast-like cell accu-
mulation (arrowheads) in Jansen transgenic mice
that express a constitutively active PTH receptor,
but not in mice expressing both transgenes at
the same time. The bar graph shows fibroblastic
measurements in the metaphyseal trabecular
regions as an indication of peritrabecular stromal
cell response. Data are represented as percent
Fb.V/BV, and error bars represent standard error,
n = 6; *p < 0.05 versus Jansen alone.
(B) PTH activates Wnt signaling in vivo even in
Dkk1 mice. Total RNA was isolated for analysis
of TOPGAL and Axin2 mRNAs from tibiae of
6-week-old TOPGAL mice with (Tg) or without
(WT) transgenic Dkk1 receiving subcutaneous
injection of human PTH(1–34) at a dose of 2 mg/kg
24 hr before sacrifice. Data are represented as
percent WT vehicle injection. Error bars represent
standard error, n = 6; *p < 0.05 versus vehicle
injection.
Cell Metabolism
Dkk1 Attenuates PTH Action on Bone In Vivoby addition of forskolin (Fsk), an activator of adenylyl cyclase/
protein kinase A (PKA) (Figures S7C and S7D). Further, with addi-
tion of recombinant Dkk1 protein or coexpression of a plasmid
directing the expression of Dkk1 in the transfected MC3T3E1
cells, the synergistic effect of Fsk on Wnt reporter activity per-
sisted, although exogenous Dkk1 in either condition substan-
tially suppressed Wnt reporter activity in response to Wnt3a
(Figures S7E and S7F). Dkk1 had no significant effect on Wnt
reporter activity stimulated by lithium chloride (LiCl) (Figure S7G),
an inhibitor of the glycogen synthase kinase 3 (GSK3), down-
stream of Dkk1 action, but both PTH and Fsk exhibited a syner-
gistic effect on Wnt reporter activity with LiCl (Figure S7H). The
synergy with the action of LiCl suggests possible actions of
PTH and Fsk distal to the stablization of b-catenin caused by
inhibition of GSK3.
We next examined whether the synergistic effect of PTH on
Wnt reporter activity was associated with an increase in nuclear
b-catenin translocation. Confocal microscopy of b-catenin in
MC3T3E1 cells showed no effect of PTH on the amount of
nuclear b-catenin, whereas Wnt3a clearly induced nuclear b-cat-
enin translocation (Figure 7A). This nonquantitative methodologyCell Metabolism 11, 161–171makes it difficult to determine whether
PTH and Wnt3a together induced higher
levels of nuclear b-catenin than Wnt3a
alone. Therefore, we used western
blot analysis after cell fractionation to
measure nuclear b-catenin levels. We
observed a small increase in b-catenin
in nuclei of the cells treated with PTH
and Wnt3a at the same time compared
to the cells treated with Wnt3a alone
(Figure 7B).
Recent studies have shown that cyclic AMP-dependent
protein kinase can phosphorylate b-catenin at the Ser-552
and Ser-675 (Hino et al., 2005; Taurin et al., 2006, 2008). In
some settings (Hino et al., 2005), PKA activation led to a stabli-
zation of b-catenin (Hino et al., 2005). However, the studies of
Taurin et al. (Taurin et al., 2006, 2008), which showed that
serine-to-alanine mutation of Ser-675 stopped the activation
of a Wnt reporter in response to PKA, also showed that this
activation occurred with no change in levels or cellular localiza-
tion of b-catenin. Consequently, we wanted to study the effects
of PTH on the PKA-mediated phosphorylation of b-catenin in
MC3T3E1 cells. After immunoprecipitation of cell lysates with
anti-b-catenin antibody, western blotting of the precipitates
with anti-PKA phosphosubstrate antibody showed a strong
increase in the band that comigrated with b-catenin after PTH
and Fsk treatment (Figure 7C), suggesting that PKA-mediated
phosphorylation of b-catenin by PTH may be an important
mechanism underlying the synergistic effect of PTH on canon-
ical Wnt signaling in MC3T3E1 osteoblasts. It remains to be
determined whether any such mechanism operates in normal
osteoblasts., February 3, 2010 ª2010 Elsevier Inc. 167
Figure 6. Effect of PTH and Wnt3a on Wnt
Target Genes and b-Catenin in Primary
Osteoblasts
(A and B) qRT-PCR analysis of Wnt target genes
(Axin2, Tcf1, and TOPGAL) in primary osteoblasts
derived from 6-week-old WT and Dkk1 transgenic
(Tg) mice that were crossed with TOPGAL mice.
Primary osteoblasts were cultured in 6-well plates
with aMEM medium supplemented with 10% FBS.
At 70% confluence, primary cells were refed with
fresh medium and 48 hr later were treated for
6 hr with vehicle (Veh), hPTH (PTH, 100 nM),
Wnt3a (Wnt, 10 ng/ml), Dkk1 (500 ng/ml), and
PTH plus Wnt3a or plus Dkk1 (A), or with Dkk1
antibody (Ab, 25 mg/ml), PTH plus Dkk1 antibody
(PTH+Ab), Wnt3a plus Dkk1 antibody (Wnt+Ab),
or PTH plus Wnt3a and Dkk1 antibody
(PTH+Wnt+Ab) (B), as indicated. a, p < 0.05 versus
vehicle; b, p < 0.05 versus Wnt3a or versus Wnt3a
plus Dkk1 antibody; c, p < 0.05 versus PTH. Same
experiment was repeated three times with similar
results.
(C) Western blot analysis of nuclear b-catenin.
Primary osteoblasts from WT tibiae were treated
with hPTH (100 nM) and/or Wnt3a (10 ng/ml),
Dkk1 (500 ng/ml) for 16 hr, and nuclear extracts
were analyzed by western blotting with anti-b-cat-
enin antibody and densitometry with AlphaImager
2200. Relative levels (bar graph) have been
obtained from three independent experiments.
*p < 0.05 versus vehicle; ˆp < 0.05 versus Wnt3a
alone (see also Figure S6).
Error bars represent standard error.
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Dkk1 Attenuates PTH Action on Bone In VivoLymphoid enhance factor 1 (Lef1) is a transcriptional regulator
of the Wnt/b-catenin signaling cascade and is activated by
nuclear b-catenin. We next examined whether the synergistic
effect of PTH on canonical Wnt signaling was partly contributed
to by PTH-modulated Lef1 expression. In MC3T3E1 cells, PTH
treatment dramatically enhanced Lef1 expression in both protein
and mRNA levels (Figures 7D and 7E), indicating an additional
potential mechanism for PTH activation of Wnt signaling.
A striking suppression of Dkk1 mRNA expression by PTH was
also observed in the MC3T3E1 cells (Figure 7E).DISCUSSION
Recent studies in vitro have shown that Wnt signaling can
mediate actions of G protein coupling receptors in many tissues
(Castellone et al., 2005; Goessling et al., 2009; Liu and Habener,
2008), but comparatively little is known about whether canonical
Wnt signaling mediates actions of the PTH receptor in vivo. Here
we use three distinct models of hyperparathyroidism in vivo to
address this question. In each model, the PTH-induced increase
in stromal cell number and bone formation is dampened or
completely blocked by overexpression of Dkk1. These three
models usefully complement each other. Each model involves
increased activation of the PTH receptor in osteoblasts but
differs dramatically in associated levels of blood calcium and
serum phosphorus. Thus, these three models together assure
that the stromal cell accumulation blocked by Dkk1 is caused
by PTH receptor activation in osteoblasts.168 Cell Metabolism 11, 161–171, February 3, 2010 ª2010 Elsevier InSeveral models could explain how Dkk1 action can block the
stromal cell response to PTH. We observed in vitro that Dkk1
suppressed proliferation and colony formation of BMSCs. It is
possible that Dkk1 diffuses and acts on osteoblast precursor
cells that may lack PTH receptors and slows the further prolifer-
ation/differentiation of these cells, thus stopping accumulation of
stromal cells in response to PTH. We have previously shown that
the Dkk1 produced in these mice diffuses into the marrow and
suppresses Wnt signaling in adjacent hematopoietic stem cells
(Fleming et al., 2008); Dkk1 might also reach very early cells in
the osteoblast lineage. In this model, a basal level of Wnt
signaling would affect the manifestations of PTH action without
also mediating actions of PTH, since the key Wnt target cells
might lack PTH receptors. Alternatively, Dkk1 overexpression
may lower the basal level of Wnt signaling in PTH target cells
to generate the observed phenotypes. Even if PTH activates
responses to Wnt signaling in these cells exposed to high levels
of Dkk1, the level of Wnt signaling may not increase sufficiently to
cause accumulation of stromal cells and to increase bone forma-
tion. In this model, PTH action requires activation of Wnt
signaling by PTH. We also cannot eliminate the possibility that
the effect of Dkk1 overexpression blocks PTH action in a way
that does not involve effect on b-catenin activation. These
models are difficult to distinguish with the available data.
Somewhat surprisingly, we found that acute administration of
PTH significantly increased canonical Wnt signaling in bone
in vivo and in primary osteoblasts even in the presence of
nonsuppressible Dkk1. We also observed that PTH and Wnt3a
together increased nuclear b-catenin and Wnt target genec.
Figure 7. Effect of PTH on b-Catenin, Lef1,
and Dkk1 in MC3T3E1 Cells
(A and B) PTH had no significant effect on nuclear
b-catenin translocation. Nuclear b-catenin locali-
zation was evaluated in MC3T3E1 cells stimulated
with vehicle, PTH (100 nM) Wnt3a (25 ng/ml), or
PTH plus Wnt3a for 24 hr, as indicated. b-catenin
was detected by immunofluorescence confocal
microscopy with anti-b-catenin antibody (A).
MC3T3E1 cells were treated with PTH, Fsk, and/
or Wnt3a at the indicated concentrations for
24 hr, and nuclear extracts were analyzed by
western blotting with anti-b-catenin antibody and
densitometry with AlphaImager 2200. Relative
levels have been obtained from three independent
experiments (B).
(C) Immunoprecipitation and western blot analysis
of PKA-mediated phosphorylation of b-catenin.
Total cell lysates from MC3T3E1 cells treated
with PTH (100 nM) or Fsk (10 mM) for 20 min
after serum-free culture for 24 hr were immunopre-
cipitated with anti-b-catenin antibody, and the
immune complexes were analyzed by western
blotting with antibodies against phosporylated
PKA substrate (PKAS) or b-catenin.
(D) Western blot analysis of Lef1 expression.
MC3T3E1 cells were treated with PTH (100 nM),
Fsk (10 mM), Wnt3a (30 ng/ml), or Fsk plus Wnt3a
(F+W) for 24 hr, and total cell lysates were
analyzed by western blotting with anti-Lef1
antibody.
(E) qRT-PCR analysis of Dkk1 and Lef1 expres-
sion. MC3T3E1 cells were treated with PTH
(100 nM) for the indicated time periods. Error
bars represent standard error, and similar results
have been obtained from three independent
experiments. *p < 0.01 versus basal (0 hr) (see
also Figure S7).
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be partly explained by PTH suppression of sclerostin expression,
which we observed in both WT and Dkk1 mice and in primary
osteoblasts after PTH administration (data not shown). Our
studies in the MC3T3E1 cell line could provide an additional
explanation for this observation, although this cell line may not
accurately reflect pathways in osteoblasts from WT mice. In
this cell line, PTH promoted Lef1 expression and also induced
PKA-mediated, activating phosphorylation of b-catenin (Hino
et al., 2005; Taurin et al., 2006, 2008).
These studies combine with previous work to suggest that PTH
signaling and Wnt signaling interact at various levels to influence
osteoblast function. We and others (Kulkarni et al., 2005) have
shown that PTH decreases the expression of Wnt antagonists,
Dkk1 and sclerostin (Bellido, 2006; Leupin et al., 2007). Further,
PTH can increase the PKA-mediated phosphorylation of Lrp6 at
GSK3 and CK1 sites to activate Wnt signaling (Wan et al., 2008).
Others have also shown that Gs, in some settings, can increase
Wnt signaling through direct binding of Gsa to Axin (Castellone
et al., 2005). It has also been shown that PKA can inactivate
GSK3 by phosphorylating GSK3 directly (Suzuki et al., 2008;
Taurin et al., 2007). Here we also show that PTH increases Lef1
expression and the activating phosphorylation of b-catenin at
a PKA target site in osteoblastic MC3T3E1 cells. Thus, PTH acts
at multiple levels in various contexts to increase Wnt signaling.Cell MOur findings highlight multiple ways that PTH and Wnt
signaling interact in intact bone. Wnt signaling is required for
high levels of PTH to stimulate formation of woven bone and
accumulation of stromal cells that probably represent osteoblast
precursors. Despite overexpression of Dkk1 that can act on
osteoblasts and marrow cells (Fleming et al., 2008), PTH can
increase Wnt signaling in osteoblasts in vivo, probably through
multiple mechanisms. The studies here did not address the
possible role of Wnt signaling in mediating other actions of
PTH in bone, such as the anabolic response to intermittently
administered PTH. Further studies will be needed to address
these questions.EXPERIMENTAL PROCEDURES
Animals
All mice, including TOPGAL (DasGupta and Fuchs, 1999), Jansen, and Dkk1
transgenic mice, were in the fifth generation of backcrossing into C57BL/6J
background and were maintained in facilities operated by the Center for
Comparative Research of the Massachusetts General Hospital. All animal
experimental procedures were approved by the institution’s Subcommittee
on Research Animal Care.
Generation of Dkk1 transgenic mouse lines is described in the Supplemental
Experimental Procedures.
To induce secondary hyperparathyroidism, mice at 3 weeks of age were
fed a low-calcium diet (0.02% calcium and 0.4% phosphorus) or theetabolism 11, 161–171, February 3, 2010 ª2010 Elsevier Inc. 169
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Dkk1 Attenuates PTH Action on Bone In Vivocorresponding control diet (0.6% calcium and 0.4% phosphorus) (Harlan Tek-
land) for 3 weeks. To mimic primary hyperparathyroidism, PTH infusion was
performed in mice at 12 weeks of age. Human PTH(1–34) was reconstituted
in a solution containing 150 mM NaCl, 1 mM HCl, and 2% heat-inactivated
mouse serum and loaded into Alzet osmotic minipumps (DURECT Corpora-
tion). The pumps were equilibrated in 0.9% NaCl overnight at 37C and
then implanted into an interscapular subcutaneous pocket under Avertin
anesthesia.
Skeletal Analysis
Skeleton analysis including in situ hybridization, TRAP, BrdU, and TUNEL
assay is described in the Supplemental Experimental Procedures.
Serum Biochemistry
Blood was collected by orbital sinus puncture before sacrifice for serum
biochemistry. Serum calcium and inorganic phosphorus were assayed with
the UV determination kits (Stanbio Laboratory). Intact immunoreactive PTH
was measured in duplicate using an ELISA kit (Immutopics Inc., San Clemente,
CA). Serum OPG and TRAP-5b were evaluated with ELISA kits from R&D
Systems, while serum PINP and CTX were measured with ELISA kits from
Immunodiagnostic Systems.
Cell Culture, Luciferase Reporter Assay, and Reagents
MC3T3E1 cells were maintained in aMEM with 10% FBS under 5% CO2 in air
and were transfected with Wnt reporter gene Super8XTOPflash or control
plasmid named Super8XTOPflash (both plasmids were kindly provided by
Dr. Randall Moon) using lipofectamine (Invitrogen). Luciferase reporter assays
in MC3T3E1 cells were carried out in 24-well plates using a Firefly Luciferase
Assay Kit (Biotium). The cells were lysed with 100 ml of lysis buffer after treat-
ment, and the lysate was used for Luminometer measurement.
Human PTH(1–34) amide was synthesized in the Biopolymer Core Labora-
tory of the Endocrine Unit, Massachusetts General Hospital. Mouse recombi-
nant Wnt3a and mouse recombinant Dkk1 were purchased from R&D
Systems. The Dkk1 antibody (kindly provided by Eli Lilly and Company) is
a mouse rat chimeric monoclonal antibody, and its functional activity was eval-
uated in UMR-106 cells with Wnt-responsive TOPflash reporter gene.
Explant Culture
Embryonic tibia and femur were cultured as described previously (Guo et al.,
2002). Briefly, each rudiment was cultured in 300 ml of a-MEM medium supple-
mented with 10% fetal bovine serum in a separate well of 24-well plate, and
PTH treatment was started 4 hr after an initial culture of the dissected rudi-
ments.
Cell Proliferation and Colony Formation
Primary bone marrow cells isolated for cell proliferation and colony formation
are described in the Supplemental Experimental Procedures.
Quantitative Real-Time PCR
Total RNA for qRT-PCR was extracted from cultured emboryonic rudiments
and tibiae and femurs (without bone marrow) at 6–12 weeks of age or from
cultured cells using Trizol reagents (Invitrogen) according to the manufac-
turer’s protocol. For qRT-PCR, cDNA was prepared with random primer
using the SuperScript First-Strand Systhesis System (Invitrogen) and analyzed
with the SYBR GreenMaster Mix (QIAGEN) in the thermal cycler with two
sets of primers specific for each targeted gene (Table S1). Relative expression
was calculated for each gene by the 2-DDCT method with Gapdh for
normalization.
Immunoprecipitation and Western Blotting
Immunoprecipitation and western blotting of nuclear extract and total cellular
protein isolated from MC3T3E1 cells for b-catenin, Lef1, and phosphorylated
PKA substrate were described previously (Taurin et al., 2006). Antibodies
were purchased from Sigma-Aldrich (anti-b-catenin) and Cell Signaling Tech-
nology (anti-Lef1 and antiphosphorylated PKA substrate).170 Cell Metabolism 11, 161–171, February 3, 2010 ª2010 Elsevier InMicrocomputed Tomography
mCT analysis of the distal femur and vertebrate (L5) was performed using
a desktop microtomographic image system, as described previously (Yang
et al., 2007).
Statistics
Statistical analyses were performed with the unpaired Student’s t test. Data
are expressed as mean ± SD or SEM, and P values smaller than 0.05 were
considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.cmet.2009.12.007.
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